Results 211 to 220 of about 231,004 (334)

YKT6 Promotes Bladder Cancer Progression by Stabilizing β‐catenin Through USP7‐Mediated Deubiquitination

Advanced Science, EarlyView.
The SNARE protein YKT6 is upregulated in bladder cancer (BLCA), correlating with poor prognosis. YKT6 promotes tumor proliferation and metastasis by activating Wnt/β‐catenin signaling. It recruits Ubiquitin‐Specific Peptidase 7 (USP7) to deubiquitinate and stabilize β‐catenin, enhancing its nuclear accumulation and driving oncogenic gene expression ...
Sheng Tu, Wenzhi Du, Yongwen Luo, Jiageng Shi, Tianyun Liu, Meng Ji, Kangping Xiong, Siming Chen, Fenfang Zhou, Mingxing Li, Jingtian Yu, Gang Wang, Lingao Ju, Yi Zhang, Yu Xiao, Xinghuan Wang, Kaiyu Qian   +16 more
wiley   +1 more source

Impact of CD68, CD4, TNF-α, and COX-2 expression on disease-specific survival in Brazilian patients with OSCC. [PDF]

Braz Oral Res
Aquino SN, Souza LL, Bezerra HKF, Alvarenga DG, Bonan PRF, Martins HDD, Santos-Silva AR, Lopes MA, Vargas PA.   +8 more
europepmc   +1 more source

How Aspirin Interferes with Cyclooxygenase Activity: the Work of William L. Smith

, 2008
Nicole Kresge, Robert Simoni, Robert L. Hill   +2 more
openalex   +1 more source

Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione‐Mediated Stemness Maintenance

Advanced Science, EarlyView.
PDAC has a poor prognosis due to chemoresistance. We revealed that MCU upregulation is associated with chemoresistance and stemness in PDAC. MCU‐mediated Ca2+ influx induced ER stress, activating the PERK‐ATF4/NRF2 axis to enhance PSAT1/SLC711 expression and glutathione synthesis, reducing ROS and maintaining stemness.
Zekun Li, Chenyang Meng, Guangcong Shen, Yueying Shan, Junjin Wang, Diliyaer Abudukeremu, Rui Zhao, Bo Ni, Chao Xu, Xiaofan Guo, Jun Yu, Kaiyuan Wang, Shengyu Yang, YunZhan Li, Yongjie Xie, Tianxing Zhou, Jihui Hao, Xiuchao Wang   +17 more
wiley   +1 more source

Retraction for Murmu et al., Dynamic antagonism between RNA-binding protein CUGBP2 and cyclooxygenase-2-mediated prostaglandin E₂ in radiation damage. [PDF]

Proc Natl Acad Sci U S A
europepmc   +1 more source

Decoding intratumoral cyclooxygenase-2 signaling through multi-omics: insights from esophageal cancer and beyond. [PDF]

Clin Exp Med
Zhuang XY, Xu DM, Chen JN, Huang XY, Wu SP, Zhang YF, He XH.   +6 more
europepmc   +1 more source

Bombesin induced cyclooxygenase-2 expression and differentiation in intestinal epithelial cells

, 2000
Yan-Shi Guo, Xiaodong Wen, Courtney M. Townsend, Mark R. Hellmich   +3 more
openalex   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

NOVEL HYBRIDS OF QUINOLINE LINKED PYRIMIDINE DERIVATIVES AS CYCLOOXYGENASE INHIBITORS: MOLECULAR DOCKING, ADMET STUDY, AND MD SIMULATION

K. DEEPTHI, Manjunatha S. Katagi, J. Fernandes, Sheshagiri R. Dixit, Deepshikha Singh   +4 more
openalex   +2 more sources

Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy

Advanced Science, EarlyView.
Heterogeneous cancer‐associated fibroblasts orchestrate dual immune microenvironments in LAGC. Abstract The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial.
Yao Lin, Xiong Sun, Chengguo Li, Ming Yang, Ke Wu, Ke Liu, Anshu Li, Xiaoming Shuai, Kailin Cai, Zheng Wang, Guobin Wang, Peng Zhang, Jianfeng Shen, Kaixiong Tao, Yuping Yin   +14 more
wiley   +1 more source